The nondiscretionary nature of cough and cold medicine will support stable industry growth, as people consistently contract viruses. Operators will continue to benefit from economies of scale, with profit margins remaining high. Nevertheless, healthcare reform will allow more people to have health insurance, resulting in more prescription drug sales in place of over-the-counter medication.
This industry manufactures over-the-counter (OTC) cough and cold treatments and suppressants. Products include systemic remedies like antihistamines and combination products, decongestants and medicated candies. The industry does not include companies that are primarily retailers, like pharmacies or department stores.
This report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry key players and their market shares.